Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T. Baron F, et al. Among authors: zwierzina h. Haematologica. 2012 Apr;97(4):529-33. doi: 10.3324/haematol.2011.044347. Epub 2011 Nov 18. Haematologica. 2012. PMID: 22102701 Free PMC article. Clinical Trial.
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group. Zwierzina H, et al. Leukemia. 2005 Nov;19(11):1929-33. doi: 10.1038/sj.leu.2403934. Leukemia. 2005. PMID: 16151466 Clinical Trial.
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suciu S, Dardenne M, Solbu G, de Witte T, Jacobs A, Visani G, et al. Gerhartz HH, et al. Among authors: zwierzina h. Leukemia. 1994 Jan;8(1):16-23. Leukemia. 1994. PMID: 8289481 Clinical Trial.
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R. de Witte T, et al. Among authors: zwierzina h. Blood. 2001 Oct 15;98(8):2326-31. doi: 10.1182/blood.v98.8.2326. Blood. 2001. PMID: 11588026 Free article. Clinical Trial.
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.
Willemze R, van der Lely N, Zwierzina H, Suciu S, Solbu G, Gerhartz H, Labar B, Visani G, Peetermans ME, Jacobs A, et al. Willemze R, et al. Among authors: zwierzina h. Ann Hematol. 1992 Apr;64(4):173-80. doi: 10.1007/BF01696219. Ann Hematol. 1992. PMID: 1581405 Clinical Trial.
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Gerhartz HH, Marcus R, Delmer A, Zwierzina H, de Witte T, Jacobs A, Visiani G, Fiere D, Sonneveld P, Labar B, et al. Gerhartz HH, et al. Among authors: zwierzina h. Infection. 1992;20 Suppl 2:S116-23. doi: 10.1007/BF01705030. Infection. 1992. PMID: 1493935 Clinical Trial.
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.
Croockewit AJ, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, Lange W, Ludwig H, Martinelli G, Mertelsmann R, Nuessler V, Willemze R, De Witte TJ, Zittoun R, Zwierzina H. Croockewit AJ, et al. Among authors: zwierzina h. Eur J Cancer. 1997 Oct;33(11):1732-46. doi: 10.1016/s0959-8049(97)00222-0. Eur J Cancer. 1997. PMID: 9470826 Review. No abstract available.
112 results